

**The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen *Candida albicans*.**

Item Type	Article
Authors	Buschart, Anna; Burakowska, Anna; Bilitewski, Ursula
Citation	The fungicide fludioxonil antagonizes fluconazole activity in the human fungal pathogen <i>Candida albicans</i> . 2012, 61 (Pt 12):1696-703 J. Med. Microbiol.
DOI	<a href="https://doi.org/10.1099/jmm.0.050963-0">10.1099/jmm.0.050963-0</a>
Journal	Journal of medical microbiology
Rights	Archived with thanks to Journal of medical microbiology
Download date	26/02/2022 19:49:39
Link to Item	<a href="http://hdl.handle.net/10033/269716">http://hdl.handle.net/10033/269716</a>



**This is a pre- or post-print of an article published in  
Buschart, A., Burakowska, A., Bilitewski, U.  
The fungicide fludioxonil antagonizes fluconazole  
activity in the human fungal pathogen *Candida albicans*  
(2012) Journal of Medical Microbiology, 61 (PART12), pp.  
1696-1703.**

1 **The fungicide fludioxonil antagonizes fluconazole activity in the human fungal**  
2 **pathogen *Candida albicans***

3  
4

5 **running title:** Fludioxonil antagonizes fluconazole in *C. albicans*

6  
7

8 **contents category:** Antimicrobial agents and chemotherapy

9  
10  
11

12 **authors:**

13 Anna Buschart, Anna Burakowska<sup>1</sup>, Ursula Bilitewski\*

14 Biological Systems Analysis, Helmholtz Centre for Infection Research, Braunschweig, Germany

15

16 **\*corresponding author:**

17 Ursula Bilitewski, Biological Systems Analysis, Helmholtz Center for Infection Research,

18 Inhoffenstr. 7, 38124 Braunschweig, Germany, e-mail: ursula.bilitewski@helmholtz-hzi.de, tel:

19 +49-(0)531-6181-1010, fax: +49-(0)531-6181-1096

20

21 **<sup>1</sup>present address:**

22 Applied Biochemistry, Leibniz Institute of Plant Genetics and Crop Plant Research (IPK),

23 Gatersleben, Germany

24

25

26

27 **abbreviations:**

28 ABC-transporter – transporters with ATP-binding cassettes

29 PDR – pleiotropic drug resistance

30 R6G – rhodamine 6G

## 31 Abstract

32

33 The fungicide fludioxonil is widely used in agriculture. Residua of this fungicide are occasionally  
34 detected in fruits and can therefore be ingested by humans.

35 The human fungal pathogen *Candida albicans* expresses the target of fludioxonil, Nik1p, a type III  
36 histidine kinase involved in stress response. Inhibition of yeast and hyphae growth was hardly  
37 observable after treatment of *C. albicans* SC5314 with fludioxonil. As a side effect, however, we  
38 observed a concentration-dependent induction of the expression of the genes *CDR1* and *CDR2* for  
39 ABC-transporters (ATP-binding cassette transporter). This was independent of the presence of the  
40 target of fludioxonil, as induction was also observed in a  $\Delta nik1$  deletion mutant. Deletion of *CDR1*  
41 aggravated the inhibition of germ tube formation by fludioxonil, indicating that, in the wild type,  
42 the fungicide was discharged from the cell by Cdr1p. Cdr1p is also known as a resistance factor of  
43 *C. albicans* against the commonly used antimycotic fluconazole.

44 Thus the effect of concurrent exposition to fludioxonil and known cargoes of ABC-transporters on  
45 their extrusion and the growth of *C. albicans* was examined. Pre-incubation with fludioxonil  
46 decreased the export rate of rhodamine 6G. The resistance to fluconazole was increased by  
47 fludioxonil, independently of Nik1p.

48 Therefore, exposition of *C. albicans* to fludioxonil may lead to increased resistance to fluconazole  
49 treatment.

50

## 51 **Introduction**

52

53 The oligomorphic yeast *C. albicans* can cause localized superficial infections as well as life-  
54 threatening systemic candidiasis in immunocompromised individuals. *C. albicans* infections  
55 accompany severe diseases, are hospital-acquired in the majority of cases and are the fourth most  
56 frequent cause of nosocomial sepsis. Thus they have become a major complication particularly in  
57 intensive care units (Pfaller and Diekema, 2007).

58 Fludioxonil is a phenylpyrrol fungicide which is widely used in agriculture, especially in the  
59 protection of grapes and berries from plant pathogenic fungi, most prominently *Botrytis cinerea*.  
60 While fludioxonil is highly toxic to some aquatic organisms, the toxicity to mammals has been low  
61 or negligible in a wide range of toxicological studies. The fungicide interacts with the osmotic stress  
62 response of filamentous fungi and yeasts by inhibiting the activity of a histidine kinase of type III  
63 (Pillonel and Meyer, 1997; Okada *et al.*, 2005; Ochiai *et al.*, 2002). A homologous histidine kinase  
64 (termed Nik1p) is expressed in the opportunistic human-pathogenic yeast *Candida albicans* (Alex  
65 *et al.*, 1998; Yamada-Okabe *et al.*, 1998) and is also targeted by fludioxonil (Buschart *et al.*, 2012).  
66 Furthermore, Nik1p has been implicated to be involved in the yeast-to-hyphae transition (Alex *et*  
67 *al.*, 1998; Yamada-Okabe *et al.*, 1999), which is a major pathogenicity factor (Calderone and Fonzi,  
68 2001). Therefore, we investigated the effect of fludioxonil on *C. albicans*. We observed in a  
69 comprehensive gene expression analysis that fludioxonil induced the expression of the ABC-  
70 transporters Cdr1p and Cdr2p.

71 The overexpression of such transporters can cause a higher resistance to antimycotic drugs, as the  
72 intracellular concentration of the antimycotic is decreased (Wirsching *et al.*, 2000; Siikala *et al.*,  
73 2010). Active transport by ABC-transporters, especially of the PDR-subfamily, is achieved by  
74 coupling ATP-hydrolysis to export (Prasad *et al.*, 1995; Sipos and Kuchler, 2006). The genome of  
75 *C. albicans* contains nine genes for PDR-subfamily ABC-transporters (according to Gaur *et al.*,  
76 2005 and the *Candida* Genome Database (Arnaud *et al.*, 2012)) and the relevance of the  
77 transporters Cdr1p and Cdr2p in resistance to fluconazole has been studied intensively (Prasad *et*  
78 *al.*, 1995; Sanglard *et al.*, 1997).

79 Fluconazole is one of the azole-antimycotics which are used to treat systemic *C. albicans* infections,  
80 besides polyenes, echinocandins, and flucytosin. Acquisition of resistance to one or several of these  
81 antimycotics has been observed (Rex *et al.*, 1995; Fournier *et al.*, 2011). Resistance to fluconazole  
82 is usually found in less than 10 % of clinical isolates of *C. albicans*, but the proportion of fully  
83 susceptible strains is below 80 % (Sanglard and Odds, 2002; Pfaller and Diekema, 2007).  
84 Cdr1p seems to be more important in fluconazole resistance than Cdr2p (Tsao *et al.*, 2009). Besides

85 fluconazole, Cdr1p is able to export human hormones, like estradiol (Krishnamurthy *et al.*, 1998a),  
86 and phospholipids (Dogra *et al.*, 1999; Smriti *et al.*, 2002; Shukla *et al.*, 2007). A higher  
87 susceptibility of a  $\Delta cdr1$  mutant pointed to Cdr1p's activity in the efflux of terbinafine,  
88 cycloheximide, brefeldin A and fluphenazine (Sanglard *et al.*, 1996).  
89 Constitutive overexpression of *CDR1* and *CDR2* is caused by mutations of the transcriptional  
90 regulator Tac1p (Coste *et al.*, 2004; Coste *et al.*, 2006). Transient upregulation of *CDR1* and *CDR2*,  
91 which also attenuates susceptibility to antimycotics, has been observed upon bio-film formation and  
92 heat shock, or exposure to hormones and some antimycotic compounds as well as agricultural  
93 herbicides (Krishnamurthy *et al.*, 1998b; Liu *et al.*, 2005; Schmidt *et al.*, 2008).  
94 Hence we studied the effect of fludioxonil on the expression of *CDR1* and *CDR2* in *C. albicans*. We  
95 found the induction of the expression of *CDR1* and *CDR2* during exposition to fludioxonil to be a  
96 target-independent side-effect. Therefore we also investigated the consequences of fludioxonil  
97 exposure for the export efficiency of antimycotic compounds and for the susceptibility of  
98 *C. albicans* to these compounds.

99

100

## 101 **Material and methods**

102

### 103 **Organisms and culture conditions**

104 *C. albicans* isolates ATCC-10231, DSM-1577 (both obtained from DSMZ-German Collection of  
105 Microorganisms and Cell Cultures) and SC5314 (ATCC MYA-2876; Gillum *et al.*, 1984), as well as  
106 the SC5314-derived deletion mutants  $\Delta cdr1$  (Nobile and Mitchell, 2009),  $\Delta cdr2$  (Sanglard *et al.*,  
107 1997),  $\Delta cdr1,2$  (Sanglard *et al.*, 1997),  $\Delta tac1$  (Homann *et al.*, 2009), and  $\Delta nik1$  (Alex *et al.*, 1998)  
108 were used in this study. Overnight cultures were prepared in 250 ml flasks with 50 ml YPD medium  
109 at 30 °C. Pre-cultures were prepared by diluting the overnight culture in 20 ml YNB (yeast nitrogen  
110 base without amino acids, 20 g l<sup>-1</sup> glucose, 0.165 M MOPS, pH 7.2, supplemented with 20 mg l<sup>-1</sup> L-  
111 histidine or L-arginine) to an OD<sub>620nm</sub> of 0.2 and incubated for 3 h until they reached the exponential  
112 growth phase. All measurements of optical density were carried out by using the microtitre plate  
113 spectrophotometer µQuant (Biotek) and sample volumes of 180 µl in standard 96-well plates.  
114 Treatment with fungicides was carried out during the subsequent main culture and appropriate  
115 solvent controls were used for comparison.

116

### 117 **Susceptibility assays**

118 Sensitivity of *C. albicans* to antifungal compounds in liquid culture were determined in microtitre

119 plates (180 µl volume). 5000 cells per ml from an exponentially growing pre-culture were incubated  
120 in YNB with dilution series of the compounds at 30 °C for 24 h and growth was determined  
121 photometrically by measuring the OD<sub>620nm</sub>. Combination effects of compounds were investigated  
122 using the respective compound mixtures. Experiments were conducted in triplicate cultures. Results  
123 from three independent experiments are reported here.

124 In addition, fluconazole sensitivity was evaluated according to the standard recommendations of  
125 EUCAST (EUCAST, 2008) using inocula containing different concentrations of fludioxonil.  
126

#### 127 **Analysis of germ tube formation**

128 *C. albicans* from an exponentially growing pre-culture were incubated in RPMI-1640 (buffered to  
129 pH 7 with 0.165 M MOPS) and supplemented with or without 20 µg ml<sup>-1</sup> fludioxonil at 37 °C for  
130 4 h. Every 60 min, a sample was analyzed microscopically. 300 to 1500 yeast cells were counted in  
131 each experiment and the portion of cells which had formed germ tubes was documented. Data from  
132 two independent experiments are presented.

133

#### 134 **Transcriptome analysis by microarray**

135 *C. albicans* from an exponentially growing pre-culture were incubated in RPMI-1640 (buffered to  
136 pH 7 with 0.165 M MOPS) and supplemented with or without 20 µg ml<sup>-1</sup> fludioxonil at 37 °C for  
137 30 min. The cells were harvested by centrifugation at 8000 \* g for 2 min, and the cell pellets were  
138 shock-frozen in liquid nitrogen. Frozen pellets were suspended in 0.6 ml RLT buffer (Qiagen) and  
139 mechanically disrupted using glass beads (425 to 600 µm, Sigma). RNA was isolated on RNeasy  
140 mini columns with added DNase (Qiagen) as recommended by the manufacturer. The quality and  
141 integrity of total RNA of the samples was controlled with the Agilent Technologies 2100  
142 Bioanalyzer (Agilent Technologies).

143 Cy3-labelled cRNA was transcribed using the QuickAmp Labeling Kit (Agilent). According to the  
144 manufacturer's recommendations, One-Color RNA Spike-In Kit (Agilent) was used as spike-in  
145 control. 600 ng labelled cRNA were hybridized to custom 8x15k microarrays from Agilent (GEO  
146 platform accession GPL15859), which contained 2-4 probes for 6203 *C. albicans* genes, as well as  
147 20 probes each for 10 spike-in controls and 336 probes for hybridisation and grid controls. The  
148 microarrays were scanned on a G2565A scanner (Agilent) and feature extraction and quality control  
149 were performed in Feature Extraction 10.7.3.1 (Agilent) using the protocol 'GE1\_107\_Sep09'.

150 Microarray design and hybridization, as well as image analysis were performed at the Microarray  
151 Core Facility of the HZI, Braunschweig.

152 Data from three biologically independent experiments were analyzed using the R/Bioconductor

153 -package limma (Gentleman *et al.*, 2004; Smyth, 2004). Between-array-normalization by a quantile-  
154 method (Bolstad *et al.*, 2003; Smyth and Speed, 2003) was followed up by averaging the intensities  
155 of replicate probes and calculation of the logarithmic fold-change and an empirical Bayes  
156 moderated t-statistic (Smyth, 2004). Gene annotation data were from Candida Genome Database  
157 (Arnaud *et al.*, 2012; C\_albicans\_SC5314\_version\_A21-s02-m03-r02\_chromosomal\_feature.tab).  
158 The raw data and results can be accessed at GEO (accession GSE39715).

159  
160

## 161 **Gene expression analysis by RT-PCR**

162 For the working culture the pre-culture was diluted to  $OD_{620} = 0.2$  in YNB supplemented with or  
163 without up to  $20 \mu\text{g ml}^{-1}$  fludioxonil. After cultivation at  $30^\circ\text{C}$  for 30 min, the cells were harvested,  
164 shock-frozen in liquid nitrogen and RNA was isolated, as described above.

165  $3 \mu\text{g}$  of total RNA was employed in reverse transcription, with superscript II RT, random and oligo-  
166 dT<sub>12-18</sub> primers, according to the manufacturer's recommendations (Invitrogen). Quantitative real-  
167 time PCR was carried out on a 96-well LightCycler® 480 system using the LightCycler® 480 SYBR  
168 Green I Master (Roche), as recommended by the manufacturer ( $95^\circ\text{C}$ ,  $60^\circ\text{C}$ , and  $72^\circ\text{C}$  for 10 s  
169 each for 45 cycles). Gene sequences were obtained from the *Candida* Genome Database (Inglis *et*  
170 *al.*, 2011), and gene-specific oligonucleotides (Table S3) were designed by Roche's Probe Library  
171 Assay Design Center and synthesized by Eurofins MWG Operon. Specificity was controlled against  
172 the *C. albicans* genome sequence by using BLAST. Real-time analysis data (crossing-points) were  
173 normalized with respect to the actin gene *ACT1* and relative gene expression levels were calculated.  
174 The average and standard deviations of the gene expression levels relative to solvent controls in  
175 three independent experiments were calculated, and the significance of the changes in gene  
176 expression was tested by Student's t-test of normalized data ( $p < 0.05$ ).

177

## 178 **Determination of rhodamine 6G in supernatants**

179 Uptake and efflux of rhodamine 6G (R6G) in *C. albicans* was determined according to a published  
180 protocol (Maesaki *et al.*, 1999). In short, *C. albicans* was precultured as described above. Cells  
181 from an exponentially growing culture were washed twice and suspended with an  $OD_{620\text{nm}}$  of 1 in  
182 20 ml PBS. After starvation for 1 h at  $30^\circ\text{C}$ ,  $10 \mu\text{M}$  R6G (equivalent to  $4.8 \mu\text{g ml}^{-1}$ ) was added and  
183 let diffuse and enrich in *C. albicans* for 30 min (diffusion phase). Cells from 12 ml suspension were  
184 then collected by centrifugation and resuspended in YNB to enable ATP production. Throughout  
185 the next 90 min (efflux phase), as well as the preceding diffusion phase, samples of 1 ml were  
186 taken, centrifuged for 1 min at 13,000 g and the supernatant was analyzed photometrically for

absorbance at 527 nm. A dilution series of R6G was used as a standard for the determination of the concentration.

## Results and Discussion

### Fludioxonil caused a mild inhibition of growth and germ tube formation in *C. albicans* SC5314

We had previously shown that the type III histidine kinase of *C. albicans*, Nik1p is the target of fludioxonil (Buschart *et al.*, 2012). However, inhibition of growth of *C. albicans* by fludioxonil is strongly dependent on the genetic background of the strain (Wesolowski *et al.*, 2010). Growth of isolate ATCC-10231 was severely inhibited by concentrations above 5 µg ml<sup>-1</sup>, while growth of the isolate DSM-1577 and of SC5314, which is most commonly used in genetic studies, were only affected at high concentrations (Fig. 1 (a)).

It was reported that Nik1p is necessary for full yeast-to-hyphae transition (Alex *et al.*, 1998; Yamada-Okabe *et al.*, 1999). For this reason, morphological analyses of *C. albicans* treated with fludioxonil were conducted. When *C. albicans* SC5314 was grown under hyphae-inducing conditions, i. e. pH 7 and 37 °C, fludioxonil caused a slight reduction in germ tube formation and growth during the first four hours of induction (Fig. 1 (b) shows data from 2 h).

### Fludioxonil induced the expression of *CDR1* and *CDR2*

To further characterise the effects of fludioxonil on *C. albicans*, changes in the gene expression of *C. albicans* grown under hyphae inducing conditions in response to treatment with 20 µg ml<sup>-1</sup> fludioxonil were analyzed. The presence of fludioxonil lead to the differential expression of relatively few genes, with only 32 genes having positive Bayes posterior log odds-ratios of differential expression (column B in Tab. S1 and Tab. S2). Among the top 20 genes ranked by the significance of their differential expression (Tab. S1), only 10 genes were annotated with a putative or proven function. In accordance with the relevance of the fludioxonil-target Nik1p for germ tube formation, the gene for a known indicator of hyphal formation, hyphal wall protein 1 (*HWP1*; Staab *et al.*, 1996; Staab and Sundstrom, 1998), was downregulated under fludioxonil treatment. We also observed the induction of ABC-transporter genes *CDR1* and *CDR2*. Below the threshold for significance, *CDR4* was also induced, while other important transporter genes, such as *MDR1* were not differentially expressed.

Due to the relevance of the ABC-transporter Cdr1p and Cdr2p for the resistance to antimycotics we

analyzed the expression of their genes under culture conditions favouring yeast growth in more detail. The expression of both *CDR1* and *CDR2* was dependent on the concentration of fludioxonil (Tab. 1). Concentrations as low as 2.2 µg ml<sup>-1</sup> led to an up-regulation of *CDR1*, hence the active concentrations for this induction were lower than the concentrations that led to a significant growth inhibition.

However, the induction of the ABC-transporter genes was independent of the presence of the histidine kinase Nik1p – which is the target of fludioxonil – as induction was also observed in the deletion mutant *Δnik1* (Fig. 2). Therefore, the induction of *CDR1* and *CDR2* is to be considered a target-independent side effect of fludioxonil in *C. albicans*.

*CDR1* and *CDR2* were expressed at a basal level similar to the wild-type in a *Δtac1* mutant (data not shown). Induction of *CDR2* expression by fludioxonil was completely dependent on the regulator Tac1p (Fig. 2), while *CDR1* was still induced significantly ( $p < 0.05$ ) in the absence of Tac1p by fludioxonil, yet to a lesser extent than in the wild type. This is in agreement with the earlier finding that Tac1p is not essential for a basal Cdr1p-expression (Coste *et al.*, 2004) and that further factors can be involved in the induction of *CDR1* (Shukla *et al.*, 2011).

In contrast to the herbicides acetochlor, metolachlor, dimethenamide and glyphosate, which were shown by Schmidt *et al.* (2008) to induce *CDR*-expression at concentrations also fungicidal or fungistatic, fludioxonil led to an induction of *CDR1* already at subinhibitory concentrations. These active concentrations were in the ranges of allowed (up to 20 µg ml<sup>-1</sup>), as well as occasionally observed (up to 1 µg ml<sup>-1</sup>), residual concentrations on fruit (Commission Regulation (EU) No 813/2011; Electronic Code of Federal Regulations, 40 C.F.R. § 180.516 (2012)).

### **Aggravation of fludioxonil-activity by deletion of *CDR1***

As both ABC-transporter genes *CDR1* and *CDR2* had been upregulated in response to fludioxonil, the effect of these transporters on the activity of fludioxonil was investigated using deletion mutants. Growth of SC5314 yeast cells was inhibited only slightly and transiently by fludioxonil, and similar results were found in deletion mutants of *CDR1* and *CDR2* (data not shown). We also tested the effect of fludioxonil on hyphae formation. As shown in Fig. 1 (b), fludioxonil strongly reduced the ability to form germ tubes in the *Δcdr1* and *Δcdr1,2*-mutants. The *Δcdr2*-mutant was affected only in a similar degree as the wild type. This indicated that the fungicide was exported out of the cell by Cdr1p in wild type cells. While the induction of *CDR2*-expression by fludioxonil was stronger than that of *CDR1*, *CDR1* seemed to play a more important role in this process, as the *Δcdr2*-mutant behaved similar to the wild type. This finding is similar to the case of fluconazole, where *CDR1* plays the bigger role in resistance (Tsao *et al.*, 2009).

255 Treatment of a mutant strain carrying a deletion in the gene *TAC1*, which codes for the known  
256 regulator of *CDR1*, also caused only a slight reduction in germ tube formation. This was in  
257 accordance with the partial induction of *CDR1*-expression in the  $\Delta tac1$ -mutant and the basal  
258 expression of *CDR1* in this mutant.

259

#### 260 **Fludioxonil influenced the export rate of rhodamine 6G**

261 The potential role of fludioxonil in drug resistance was evaluated by studying the effect of  
262 fludioxonil on the export efficiency of the ABC-transporters in extrusion of a known cargo,  
263 rhodamine 6G (R6G; Maesaki *et al.*, 1999).

264 4.8  $\mu\text{g ml}^{-1}$  R6G was added to de-energized cells and taken up by passive diffusion, as observed via  
265 the absorbance of the culture-supernatant. The rapid diffusion rate was unchanged in the presence of  
266 20  $\mu\text{g ml}^{-1}$  fludioxonil in comparison to control cultures as the supernatant contained less than  
267 250  $\text{ng ml}^{-1}$  R6G in each case after 30 min. It was also the same for the wild type and the  $\Delta nik1$   
268 mutant.

269 After transfer into glucose-containing medium, *C. albicans* was able to produce ATP needed for the  
270 export of R6G by the ABC-transporters. Consequently, R6G was exported actively with an  
271 extrusion rate higher than the inward diffusion, resulting in a net efflux, which was visible from the  
272 increase in absorbance of the supernatant. Cultures, which were treated with fludioxonil during the  
273 efflux phase, displayed a decreased R6G efflux rate in comparison to control cultures (Fig. 3 (a)).  
274 Fludioxonil, which had been added during the diffusion phase of the experiment, had the same  
275 effect as fludioxonil added during the efflux-phase of the experiment (data not shown). However,  
276 R6G efflux was increased, if the pre-cultures had been treated with fludioxonil before loading with  
277 R6G (Fig. 3 (a)).

278 These results can be explained by competition of R6G with fludioxonil for binding sites within the  
279 ABC-transportes. When fludioxonil and R6G are added simultaneously to *C. albicans*, only the  
280 basal efflux capacity is available for both compounds. This resulted in a decelerated efflux rate for  
281 R6G. Pre-incubation of the cells with fludioxonil before starvation and loading with R6G led to the  
282 increased expression of *CDR1*, and thus, increased efflux capacity. This could be observed after  
283 supplying the cells with glucose as an energy source.

284 The changes in R6G-efflux rates in the presence of fludioxonil observed in the wild type were also  
285 detected in the  $\Delta nik1$  mutant (Fig. 3 (b)), pointing again to the fact that this effect is independent of  
286 Nik1p.

287

#### 288 **The growth inhibitory effect of rhodamine 6G was not significantly altered by fludioxonil**

289 As R6G is toxic to *C. albicans* and could not be extruded as effectively by *C. albicans*  
290 simultaneously treated with fludioxonil, the effect of fludioxonil on the toxicity of R6G was  
291 examined. Only with high concentrations of fludioxonil, a slight increase of the growth inhibitory  
292 effect of R6G was detected (Tab. 1). Therefore, the attenuation of R6G export by fludioxonil did not  
293 lead to a synergistic effect between the two substances.

294

#### 295 **The resistance to fluconazole was increased by fludioxonil**

296 Another known cargo of the ABC-transporters of *C. albicans* is the antimycotic fluconazole  
297 (Sanglard *et al.*, 1995). As the ABC-transporters play a vital role in resistance development against  
298 this drug, the effect of fludioxonil on the susceptibility to fluconazole was also analyzed.  
299 Concurrent exposition of *C. albicans* SC5314, as well as the fludioxonil resistant isolate DSM-  
300 1577, to fludioxonil and fluconazole led to an increase in fluconazole resistance by approximately a  
301 factor of 3 (Tab. 1). This effect was also observed in a standardized susceptibility assay using the  
302 EUCAST method (EUCAST, 2008), where a change of MICs from 0.5  $\mu\text{g ml}^{-1}$  (control) to 4  $\mu\text{g ml}^{-1}$   
303 (treated with 20  $\mu\text{g ml}^{-1}$ ) was observed. The effect was dependent on the concentration of  
304 fludioxonil and the active concentration range corresponded to the concentration range that was  
305 sufficient to trigger induction of *CDR1* expression. Thus, like the induction of *CDR1* expression,  
306 increased resistance to fluconazole was caused by fludioxonil concentrations within allowed  
307 maximum residue levels.

308 While the exposure to fludioxonil led to a decrease in susceptibility to fluconazole, the activity of  
309 rhodamine 6G was slightly enhanced, as described above. This may be explained by an interaction  
310 of fluconazole and R6G with different subdomains of the ABC-transporters, which was revealed by  
311 a recent study of hybrid ABC-transporters (Tanabe *et al.*, 2011). Therefore, fludioxonil may  
312 compete with R6G for binding sites and the binding site for fludioxonil seems to be closer related to  
313 that of R6G.

314

#### 315 **The fludioxonil-induced decrease in fluconazole susceptibility was independent of Nik1p, but** 316 ***CDR1* was essential for fluconazole resistance**

317 The factors responsible for the increase of resistance to fluconazole due to fludioxonil exposure  
318 were further analyzed using deletion mutants. An earlier study had indicated the histidine kinase  
319 Chk1p and a response regulator, Ssk1p, from *C. albicans* to be involved in resistance to  
320 fluconazole, as the uptake of the drug and thus the intracellular concentrations of the drug, as well  
321 as the susceptibility were increased in knock-out mutants of the respective mutants (Chauhan *et al.*,  
322 2007). However, the basal susceptibility to fluconazole was alike in the wild type and  $\Delta nik1$ -

mutant. Moreover, we observed a fludioxonil-triggered increase of fluconazole resistance, which was in accordance with the induction of *CDR1* and *CDR2*. We assume this increased the efflux capacity for fluconazole. Both observations were independent of the presence of the histidine kinase Nik1p, which is the known target of fludioxonil (Tab. 2). The difference of the roles of Nik1p and Chk1p in fluconazole susceptibility is likely due to activation of different signal transduction pathways, which is generally assumed because of phenotypical differences in the respective deletion mutants (Chauhan and Calderone, 2008).

The antagonistic effect of fludioxonil was observed in all analyzed deletion mutants with the exception of those carrying deletions in *CDR1* (Tab. 2). The  $\Delta cdr1$  mutants were, as expected, hypersensitive to fluconazole. The decrease in susceptibility to fluconazole caused by fludioxonil was not dependent on the known activator of *CDR1* expression Tac1p. This was in agreement with the finding that *CDR1* was expressed and at least partially induced by fludioxonil in a  $\Delta tac1$  mutant (Fig. 2). As the involvement of further transcription factors in *CDR1*-induction has been shown (Shukla *et al.*, 2011), fludioxonil-triggered *CDR1*-induction is likely promoted by another transcription factor in addition to Tac1p.

## Conclusion

Exposure of *C. albicans* to the fungicide fludioxonil triggered a concentration dependent induction of the expression of ABC-transporter genes *CDR1* and *CDR2*, which are involved in resistance to antimycotics such as fluconazole. As a consequence the resistance of *C. albicans* to fluconazole increased, so that fludioxonil indirectly antagonized the activity of fluconazole. This induction effect occurred at sub-growth-inhibitory concentrations of the fungicide. It was also independent of the primary target of fludioxonil in *C. albicans*, the histidine kinase Nik1p, which is involved in morphological changes as well as in stress response.

## Acknowledgements

The authors thankfully acknowledge those who contributed *C. albicans* strains: *C. albicans*  $\Delta cdr2$  and  $\Delta cdr1,2$  were kindly provided by D. Sanglard (University Hospital Lausanne, Switzerland). *C. albicans*  $\Delta nik1$  was kindly provided by C.P. Selitrennikoff (University of Colorado, USA).  $\Delta cdr1$  and  $\Delta tac1$  were obtained from the Fungal Genomics Stock Center (Kansas City, Missouri USA). The authors also thank Robert Geffers (Array Facility, HZI) for design of the microarrays employed in this study, as well as Petra Hagendorff and Sabrina Kaser (Array Facility, HZI) for

357 technical assistance with RNA quality control. This work was supported by the German Ministry of  
358 Research – project “Novel drugs against fungal human pathogens” (0315221A to A.B.).

359

360

## 361 **References**

362

363 **Alex, L.A., Korch, C., Selitrennikoff, C.P., Simon, M.I. (1998).** COS1, a two-component  
364 histidine kinase that is involved in hyphal development in the opportunistic pathogen *Candida*  
365 *albicans*. *Proc Natl Acad Sci USA* **95**, 7069-73.

366

367 **Arnaud, M.B., Inglis, D.O., Skrzypek, M.S., Binkley, J., Shah, P., Binkley, G., Miyasato, S.R.,**  
368 **Simison, M., Sherlock, G.** *Candida* Genome Database. <http://www.candidagenome.org/> (accessed  
369 17 april 2012).

370

371 **Bolstad, B.M., Irizarry, R.A., Astrand, M., Speed, T.P. (2003).** A comparison of normalization  
372 methods for high density oligonucleotide array data based on variance and bias. *Bioinformatics* **19**,  
373 185-93.

374

375 **Buschart, A., Gremmer, K., El-Mowafy, M., van den Heuvel, J., Müller, PP., Bilitewski, B.,**  
376 **(2012).** A novel functional assay for fungal histidine kinases group III reveals the role of HAMP  
377 domains for fungicide sensitivity. *J Biotechnol* **157**, 268-77.

378

379 **Calderone, R.A., Fonzi, W.A. (2001).** Virulence factors of *Candida albicans*. *Trends Microbiol* **9**,  
380 327-35.

381

382 **Chauhan, N., Calderone, R. (2008).** Two-component signal transduction proteins as potential drug  
383 targets in medically important fungi. *Infect Immun* **76**, 4795-4803.

384

385 **Chauhan, N., Kruppa, M., Calderone, R. (2007).** The Ssk1p response regulator and Chk1p  
386 histidine kinase mutants of *Candida albicans* are hypersensitive to fluconazole and voriconazole.  
387 *Antimicrob Agents Chemother* **51**, 3747-51.

388

389 **Coste, A.T., Karababa, M., Ischer, F., Bille, J., Sanglard, D. (2004).** *TAC1*, transcriptional  
390 activator of *CDR* genes, is a new transcription factor involved in the regulation of *Candida albicans*

391 ABC transporters *CDR1* and *CDR2*. *Eukaryot Cell* **3**, 1639-52.

392

393 **Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille,**  
394 **J., Sanglard, D. (2006).** A mutation in Tac1p, a transcription factor regulating *CDR1* and *CDR2*, is  
395 coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in *Candida*  
396 *albicans*. *Genetics* **172**, 2139-56.

397

398 **Dogra, S., Krishnamurthy, S., Gupta, V., Dixit, B.L., Gupta, C.M., Sanglard, D., Prasad, R.,**  
399 **(1999).** Asymmetric distribution of phosphatidylethanolamine in *C. albicans*: possible mediation by  
400 *CDR1*, a multidrug transporter belonging to ATP binding cassette (ABC) superfamily. *Yeast* **15**,  
401 111-21.

402

403 **EUCAST (2008).** EUCAST Definitive Document EDef 7.1: method for the determination of  
404 broth dilution MICs of antifungal agents for fermentative yeasts. *Clin Microbiol Infect* **14**, 398-405.

405

406 **The European Commision, 2011.** Commission Regulation (EU) No 813/2011 of 11 August 2011  
407 amending Annexes II and III to Regulation (EC) No 396/2005 of the European Parliament and of  
408 the Council as regards maximum residue levels for acequinocyl, emamectin benzoate,  
409 ethametsulfuron-methyl, flubendiamide, fludioxonil, kresoxim-methyl, methoxyfenozide,  
410 novaluron, thiacloprid and trifloxystrobin in or on certain products.

411

412 **Fournier, P., Schwebel, C., Maubon, D., Vesin, A., Lebeau, B., Foroni, L., Hamidfar-Roy, R.,**  
413 **Cornet, M., Timsit, J.F., Pelloux, H. (2001).** Antifungal use influences *Candida* species  
414 distribution and susceptibility in the intensive care unit. *J Antimicrob Chemother* **66**, 2880-6.

415

416 **Gaur, M., Choudhury, D., Prasad, R. (2005).** Complete inventory of ABC proteins in human  
417 pathogenic yeast, *Candida albicans*. *J. Mol Microbiol Biotechnol* **9**, 3-15.

418

419 **Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B.,**  
420 **Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R.,**  
421 **Leisch, F., Li, C., Maechler, M., Rossini, A.J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L.,**  
422 **Yang, J.Y.H., Zhang, J., (2004).** Bioconductor: open software development  
423 for computational biology and bioinformatics. *Genome Biol* **5**, R80.

424

425 **Gillum, A.M., Tsay, E.Y., Kirsch, D.R. (1984).** Isolation of the *Candida albicans* gene for  
 426 orotidine-5'-phosphate decarboxylase by complementation of *S. cerevisiae* *ura3* and *E. coli* *pyrF*  
 427 mutations. *Mol Gen Genet* **198**, 179-82.

428

429 **Homann, O.R., Dea, J., Noble, S.M., Johnson, A.D. (2009).** A phenotypic profile of the *Candida*  
 430 *albicans* regulatory network. *PLoS Genet* **5**, e1000783.

431

432 **Inglis, D.O., Arnaud, M.B., Binkley, J., Shah, P., Skrzypek, M.S., Wymore, F., Binkley, G.,**  
 433 **Miyasato, S.R., Simison, M., Sherlock, G. (2001).** The *Candida* genome database incorporates  
 434 multiple *Candida* species: multispecies search and analysis tools with curated gene and protein  
 435 information for *Candida albicans* and *Candida glabrata*. *Nucleic Acids Res* **40**, D667-74.

436

437 **Karnani, N., Gaur, N.A., Jha, S., Puri, N., Krishnamurthy, S., Goswami, S.K.,**  
 438 **Mukhopadhyay, G., Prasad, R. (2004).** SRE1 and SRE2 are two specific steroid-responsive  
 439 modules of *Candida* drug resistance gene 1 (*CDR1*) promoter. *Yeast* **21**, 219-39.

440

441 **Krishnamurthy, S., Gupta, V., Snehlata, P., Prasad, R. (1998a).** Characterization of human  
 442 steroid hormone transport mediated by Cdr1p, a multidrug transporter of *Candida albicans*,  
 443 belonging to the ATP binding cassette super family. *FEMS Microbiol Lett* **158**, 69-74.

444

445 **Krishnamurthy, S., Gupta, V., Prasad, R., Panwar, S.L., Prasad, R. (1998b).** Expression of  
 446 *CDR1*, a multidrug resistance gene of *Candida albicans*: transcriptional activation by heat shock,  
 447 drugs and human steroid hormones. *FEMS Microbiol Lett* **160**, 191-7.

448

449 **Liu, T.T., Lee, R.E.B., Barker, K.S., Lee, R.E., Wei, L., Homayouni, R., Rogers, P.D. (2005).**  
 450 Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine  
 451 antifungal agents in *Candida albicans*. *Antimicrob Agents Chemother* **49**, 2226-36.

452

453 **Maesaki, S., Marichal, P., Vanden Bossche, H., Sanglard, D., Kohno, S. (1999).** Rhodamine 6G  
 454 efflux for the detection of *CDR1*-overexpressing azole-resistant *Candida albicans* strains. *J*  
 455 *Antimicrob Chemother* **44**, 27-31.

456

457 **Nobile, C.J., Mitchell, A.P. (2009).** Large-scale gene disruption using the UAU1 cassette. *Methods*  
 458 *Mol Biol* **499**, 75-94.

459

460 **Ochiai, N., Fujimura, M., Oshima, M., Motoyama, T., Ichiishi, A., Yamada-Okabe, H.,**  
 461 **Yamaguchi, I. (2002).** Effects of iprodione and fludioxonil on glycerol synthesis and hyphal  
 462 development in *Candida albicans*. *Biosci Biotechnol Biochem* **66**, 2209-15.

463

464 **Okada, A., Banno, S., Ichiishi, A., Rimura, M., Yamaguchi, I., Fujimura, M. (2005).**  
 465 Pyrrolnitrin interferes with osmotic signal transduction in *Neurospora crassa*. *J Pestic Sci* **30**, 378-  
 466 83.

467

468 **Pfaller, M.A., Diekema, D.J. (2007).** Epidemiology of invasive candidiasis: a persistent public  
 469 health problem. *Clin Microbiol Rev* **20**, 133-63.

470

471 **Pillonel, C., Meyer, T. (1997).** Effect of phenylpyrroles on glycerol accumulation and protein  
 472 kinase activity of *Neurospora crassa*. *Pestic Sci* **49**, 229-36.

473

474 **Prasad, R., Wergifosse, P.D., Goffeau, A., Balzi, E. (1995).** Molecular cloning and  
 475 characterization of a novel gene of *Candida albicans*, *CDR1*, conferring multiple resistance to drugs  
 476 and antifungals. *Curr Genet* **27**, 320-9.

477

478 **Rex, J.H., Rinaldi, M.G., Pfaller, M.A. (1995).** Resistance of *Candida* species to fluconazole.  
 479 *Antimicrob Agents Chemother* **39**, 1-8.

480

481 **Sanglard, D., Ischer, F., Monod, M., Bille, J. (1996).** Susceptibilities of *Candida albicans*  
 482 multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.  
 483 *Antimicrob Agents Chemother* **40**, 2300-5.

484

485 **Sanglard, D., Ischer, F., Monod, M., Bille, J. (1997).** Cloning of *Candida albicans* genes  
 486 conferring resistance to azole antifungal agents: characterization of *CDR2*, a new multidrug ABC  
 487 transporter gene. *Microbiology* **143**, 405-16.

488

489 **Sanglard, D., Odds, F.C. (2002).** Resistance of *Candida* species to antifungal agents: molecular  
 490 mechanisms and clinical consequences. *Lancet Infect Dis* **2**, 73-85.

491

492 **Schmidt, M., Barker, S., Essmann, M., Larsen, B. (2008).** Effect of commonly used herbicides

493 on the virulence factor *CDR1* in *Candida albicans*. *Environ Toxicol Chem* **27**, 2346-51.

494

495 **Shukla, S., Rai, V., Saini, P., Banerjee, D., Menon, A.K., Prasad, R. (2007).** *Candida* drug

496 resistance protein 1, a major multidrug ATP binding cassette transporter of *Candida albicans*,

497 translocates fluorescent phospholipids in a reconstituted system. *Biochemistry* **46**, 12081-90.

498

499 **Shukla, S., Yadav, V., Mukhopadhyay, G., Prasad, R. (2011).** Ncb2 is Involved in Activated

500 Transcription of *CDR1* in Azole Resistant Clinical Isolates of *Candida albicans*. *Eukaryot Cell* **10**,

501 1357-66.

502

503 **Siikala, E., Rautemaa, R., Richardson, M., Saxen, H., Bowyer, P., Sanglard, D. (2010).**

504 Persistent *Candida albicans* colonization and molecular mechanisms of azole resistance in

505 autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. *J*

506 *Antimicrob Chemother* **65**, 2505-13.

507

508 **Sipos, G., Kuchler, K. (2006).** Fungal ATP-binding cassette (ABC) transporters in drug resistance

509 & detoxification. *Curr Drug Targets* **7**, 471-81.

510

511 **Smriti, Krishnamurthy, S., Dixit, B.L., Gupta, C.M., Milewski, S., Prasad, R. (2002).** ABC

512 transporters Cdr1p, Cdr2p and Cdr3p of a human pathogen *Candida albicans* are general

513 phospholipid translocators. *Yeast* **19**, 303-18.

514

515 **Smyth, G.K., (2004).** Linear models and empirical bayes methods for assessing differential

516 expression in microarray experiments. *Stat Appl Genet Mol Biol* **3** Article3.

517

518 **Smyth, G.K., Speed, T. (2003).** Normalization of cDNA microarray data. *Methods* **31**, 265-73.

519

520 **Staab, J.F., Ferrer, C.A., Sundstrom, P. (1996).** Developmental expression of a tandemly

521 repeated, proline-and glutamine-rich amino acid motif on hyphal surfaces on *Candida albicans*. *J*

522 *Biol Chem* **271**, 6298-305.

523

524 **Staab, J.F., Sundstrom, P. (1998).** Genetic organization and sequence analysis of the hypha-

525 specific cell wall protein gene *HWP1* of *Candida albicans*. *Yeast* **14**, 681-6.

526

527 **Tanabe, K., Lamping, E., Nagi, M., Okawada, A., Holmes, A.R., Miyazaki, Y., Cannon, R.D.,**  
528 **Monk, B.C., Niimi, M. (2011).** Chimeras of *Candida albicans* Cdr1p and Cdr2p reveal features of  
529 pleiotropic drug resistance transporter structure and function. *Mol Microbiol* **82**, 416-33.  
530

531 **Tsao, S., Rahkhoodaee, F., Raymond, M. (2009).** Relative contributions of the *Candida albicans*  
532 ABC transporters Cdr1p and Cdr2p to clinical azole resistance. *Antimicrob Agents Chemother* **53**,  
533 1344-52.  
534

535 **Wesolowski, J., Hassan, R.Y.A., Reinhardt, K., Hodde, S., Bilitewski, U. (2010).** Antifungal  
536 compounds redirect metabolic pathways in yeasts: metabolites as indicators of modes of action. *J*  
537 *Appl Microbiol* **108**, 462-71.  
538

539 **Wirsching, S., Michel, S., Morschhäuser, J. (2000).** Targeted gene disruption in *Candida albicans*  
540 wild-type strains: the role of the *MDR1* gene in fluconazole resistance of clinical *Candida albicans*  
541 isolates. *Mol Microbiol* **36**, 856-65.  
542

543 **Yamada-Okabe, T., Mio, T., Ono, N., Kashima, Y., Matsui, M., Arisawa, M., Yamada-Okabe,**  
544 **H. (1999).** Roles of three histidine kinase genes in hyphal development and virulence of the  
545 pathogenic fungus *Candida albicans*. *J Bacteriol* **181**, 7243-7.

## 546 Tables

547

548 Table 1: Concentration dependent effects of fludioxonil on growth, the expression of *CDR1* and  
549 *CDR2* and the susceptibility to fluconazole and rhodamine 6G.

	DSM-1577	SC5314			
Fludioxonil [ $\mu\text{g ml}^{-1}$ ]	$\text{IC}_{50}^{\dagger} \pm \text{sd } [\mu\text{g ml}^{-1}]$	$\text{IC}_{50}^{\dagger} \pm \text{sd } [\mu\text{g ml}^{-1}]$		Regulation <sup>‡</sup> [log <sub>2</sub> fold change $\pm$ sd]	
	fluconazole	fluconazole	rhodamine 6G	<i>CDR1</i>	<i>CDR2</i>
0	$0.1 \pm 0.0$	$0.3 \pm 0.1$	$0.5 \pm 0.2$	– <sup>§</sup>	– <sup>§</sup>
0.25	$0.2 \pm 0.2$	$0.5 \pm 0.3$	$0.6 \pm 0.1$	$1.0 \pm 0.5$	$0.4 \pm 0.4$
0.74	$0.3 \pm 0.3$	$0.7 \pm 0.1^*$	$0.6 \pm 0.1$	$2.2 \pm 1.9$	$1.6 \pm 1.4$
2.2	$0.5 \pm 0.4$	$0.7 \pm 0.1^*$	$0.5 \pm 0.1$	$2.3 \pm 0.8^*$	$4.5 \pm 2.2$
6.7	$0.5 \pm 0.3^*$	$0.7 \pm 0.2^*$	$0.5 \pm 0.2$	$3.0 \pm 1.1^*$	$6.4 \pm 2.0^*$
20	$0.6 \pm 0.1^*$	$0.9 \pm 0.1^*$	$0.5 \pm 0.2$	$3.2 \pm 0.8^*$	$5.5 \pm 1.7^*$

550 <sup>†</sup>IC<sub>50</sub> values were determined photometrically after growth of 5000 cells per ml for 24 h.

551 <sup>‡</sup>Gene expression as compared to untreated cells was measured by qRT-PCR after 30 min treatment.

552 <sup>§</sup>Reference samples for gene expression.

553 \* p < 0.05

554 sd: standard deviation

555

556 Table 2:

557 Effect of fludioxonil on the susceptibility of *C. albicans* deletion mutants to fluconazole.

Fludioxonil [ $\mu\text{g ml}^{-1}$ ]	$\text{IC}_{50} \pm \text{sd of fluconazole}^{\dagger} [\mu\text{g ml}^{-1}]$					
	SC5314	$\Delta\text{nik1}$	$\Delta\text{cdr1}$	$\Delta\text{cdr2}$	$\Delta\text{cdr1}, \Delta\text{cdr2}$	$\Delta\text{tac1}$
0	$0.3 \pm 0.1$	$0.3 \pm 0.0$	<0.05	$0.2 \pm 0.1$	$0.08 \pm 0.01$	$0.4 \pm 0.2$
0.25	$0.5 \pm 0.3$	$0.6 \pm 0.2$	<0.05	$0.6 \pm 0.1^*$	$0.08 \pm 0.01$	$0.8 \pm 0.2^*$
0.74	$0.7 \pm 0.1^*$	$0.7 \pm 0.3$	<0.05	$0.7 \pm 0.0^*$	$0.08 \pm 0.01$	$0.9 \pm 0.1^*$
2.2	$0.7 \pm 0.1^*$	$0.7 \pm 0.1^*$	<0.05	$0.8 \pm 0.1^*$	$0.08 \pm 0.01$	$0.7 \pm 0.2$
6.7	$0.7 \pm 0.2^*$	$0.7 \pm 0.4$	$0.05 \pm 0.02$	$0.9 \pm 0.1^*$	$0.09 \pm 0.01$	$0.8 \pm 0.1^*$
20	$0.9 \pm 0.1^*$	$0.9 \pm 0.4$	$0.08 \pm 0.01$	$1.2 \pm 0.7$	$0.09 \pm 0.02$	$0.7 \pm 0.1$

558 <sup>†</sup>IC<sub>50</sub> values were determined photometrically after growth of 5000 cells per ml for 24 h.

559 \*p < 0.05

560 sd: standard deviation

561 **Figure legends**

562

563 Figure 1: (a) Growth inhibitory effect of fludioxonil is dependent on the strain of *C. albicans*. Wild  
564 type isolates SC5314 (circles), ATCC-10231 (squares) and DSM-1577 (diamonds) were incubated  
565 with a dilution series of fludioxonil for 24 hours, before growth (displayed as % of untreated  
566 control) was determined photometrically. (b) Effect of 20  $\mu\text{g ml}^{-1}$  fludioxonil (grey bars) on the  
567 germ tube formation of *C. albicans* SC5314 and deletion mutants; white bars; untreated controls.  
568 Data are from microscopical analysis after 2 h of incubation in RPMI-1640 at 37 °C. Fludioxonil  
569 caused a strong inhibition of germ tube formation in strains lacking *CDR1*. Data of 750 to 2200  
570 cells from two independent experiments are shown. Total cell numbers are set as 100 %.

571

572 Figure 2: Induction of *CDR1* and *CDR2* expression in response to treatment with 20  $\mu\text{g ml}^{-1}$   
573 fludioxonil in *C. albicans* SC5314 (WT) and deletion mutants  $\Delta\text{nik1}$  and  $\Delta\text{tac1}$ . Fludioxonil-  
574 dependent induction of *CDR1* and *CDR2* was independent of Nik1p. Data from three independent  
575 experiments.

576


577 Figure 3: Effect of fludioxonil on the active Cdr-mediated export of rhodamine 6G. R6G was  
578 photometrically detected in the supernatant as described in the materials and methods section.  
579 (a) Treatment with fludioxonil during the efflux phase (triangles) decreased the efflux rate in  
580 comparison to control cultures (filled circles), while treatment of the preculture with fludioxonil  
581 increased Cdr-activity (empty circles); data from one representative of at least three experiments are  
582 shown. (b) The decrease of Cdr-efficiency in the presence of fludioxonil observed in the wild type  
583 (white bars) was also detected in the  $\Delta\text{nik1}$  mutant (grey bars); data after 60 min efflux from three  
584 independent experiments.

585

586 **Figures**

587


588 Figure 1:



589

590


591 Figure 2:



592

593

594 **Figure 3:**



595